panitumumab
takeda,amgen
['paradigm', 'rectal', 'colorectal']
 instead of paradigm alone as a study, i d say that this #asco22 is a paradigm shift for the subset of pts with #colorectalcancer who are candidates for egfr 1st-line: left ras raf her2 for our &amp; my #sciart. 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22